Business

Pharmaceutical company adds cancer drug

Posted May 20, 2021 11:00 pm

LAKE ZURICH - Fresenius Kabi Friday announced the immediate availability in the United States of its new generic cancer drug, Temsirolimus injection.

Temsirolimus, for the treatment of renal cancer, is the latest addition to the company's large U.S. portfolio of generic injectable oncology products, the company said.

Fresenius Kabi's Temsirolimus injection is supplied as a kit including one vial of 25 mg/mL Temsirolimus solution and one vial of diluent.

"Fresenius Kabi is committed to expanding affordable treatment options for patients," said John Ducker, president and CEO of Fresenius Kabi USA. "The addition of Temsirolimus is the most recent example of our development program and deep expertise in oncology medicines."

Temsirolimus is a generic version of the brand Torisel, which is used to treat advanced renal cell carcinoma.

Article Comments

Article Categories
Business Health Care

Article Comments

Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.